|Articles|October 1, 2018

Does being an orphan speed up FDA approval?

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO

ByNicholas Jacobus

June 10th 2026

The New Capital of Care in Rare Disease

ByRob Freishtat, MD,Casey McPherson

June 10th 2026

a young girl with atopic dermatitis in the acute stage. redness and scratching up to blood on the body close-up. Dermatology | Image credit: © Ksenia Kirillovykh - © Ksenia Kirillovykh - stock.adobe.com

FDA Clears Every-8-Week Lebrikizumab Maintenance Dosing in Atopic Dermatitis

ByFeliza Mirasol

June 10th 2026

The Next Frontier for AI in Health Care Is the Factory Floor

ByBrendan O'Callaghan

June 10th 2026

AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly

ByNicholas Jacobus

June 10th 2026

Does being an orphan speed up FDA approval?

Related Content

Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO

The New Capital of Care in Rare Disease

FDA Clears Every-8-Week Lebrikizumab Maintenance Dosing in Atopic Dermatitis

The Next Frontier for AI in Health Care Is the Factory Floor

AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly

Trending on PharmExec

Parabilis Medicines Raises $670 Million in Initial Public Offering

What 10 Years of Clinical Research Growth in Puerto Rico Have Taught Us

The Regulatory Landscape for Rare Pediatric Diseases

CMS ACCESS Model: Changing the Landscape of Disease Management

From Dashboards to Decisions: How AI Is Reshaping Pharma Brand Strategy